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Obesity hypoventilation syndrome (OHS) is a serious disorder characterized by daytime
hypercapnia, disordered breathing, and a reduction in chemosensitivity. Vertical sleeve gastrectomy
(VSG), a bariatric surgical procedure resulting in weight loss and weight-independent improvements
in glucose metabolism, has been observed to substantially improve sleep-disordered breathing.
However, it is unclear if the ventilatory effects of VSG are secondary to weight loss or the marked
change in metabolic physiology. Using preclinical mouse models, we found that VSG leads to an
improvement in the hypercapnic ventilatory response (HCVR) and reductions in circulating leptin
levels independent of reductions in body mass, fat mass, and caloric intake. In the absence of
leptin, VSG continues to improve body mass, fat mass, and glucose tolerance in ob/ob mice but no
longer affects HCVR. However, the HCVR of ob/ob mice can be returned to wild-type levels with
leptin treatment. These data demonstrate that VSG improves chemosensitivity and ventilatory
drive via a leptin-dependent mechanism. Clinically, these data downgrade the relative contribution
of physical, mechanical load in the pathogenesis of OHS, and instead point to physiological
components of obesity, including alterations in leptin signaling, as key drivers in OHS.

Introduction
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Obesity hypoventilation syndrome (OHS) effects approximately 30% of the obese population and if
untreated increases mortality by 2.5-fold (1). A diagnosis of OHS requires the presentation of obesity
(e.g., body mass index [BMI] ≥ 30 kg/m2), daytime elevations in the partial pressure of carbon dioxide
(PaCO2), reductions in oxygen (PaO2), and sleep-disordered breathing. Of those diagnosed with OHS, 90%
exhibit obstructive sleep apnea (OSA) (2). Individuals with OHS also exhibit reductions in their ventilatory
response to hypercapnia and hypoxia, pointing to a centrally impaired chemosensitivity response (2).
Undoubtedly, obesity is critical in the pathogenesis of OHS. Clinical analysis of the relationship
between BMI and PaCO2 in OHS individuals indicates that hypercapnia is unlikely to occur in an individual with a BMI below 30 kg/m2 (2). Moreover, individuals with OHS who undergo weight loss exhibit modest improvements in OHS (3), including reductions in daytime PaCO2 and improved chemosensitivity (4).
However, it is unclear if the mechanical load of obesity and/or the metabolic disturbances imposed by obesity contribute to the blunted chemosensitivity and disordered breathing observed in individuals with OHS.
Previous clinical research indicates that fat mass imposes a physical, mechanical load on respiratory
muscles which in turn can lead to hypoventilation (5). However, increases in fat mass rarely occur without
significant changes to an individual’s metabolic physiology. Of note, obesity results in significantly elevated leptin levels and, in some cases, glucose intolerance. Leptin, a satiety hormone positively correlated to
fat mass, conveys adiposity information to the brain. Interestingly, leptin has been found to compensate
for increased mechanical loads on the diaphragm by stimulating the ventilatory drive in ob/ob mice (6).
It is possible that a breakdown in leptin signaling, potentially through obesity-induced leptin resistance (7),
directly contributes to the pathogenesis of OHS independent of the physical, mechanical load of obesity.
Indeed, a number of preclinical approaches have linked leptin action to chemosensitivity and disordered
breathing (8–11). Alternatively, leptin may indirectly improve chemosensitivity and disordered breathing
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through its effect on glucose metabolism (12), as both clinical and preclinical studies have reported links
between glycemic control and insulin action on chemosensitivity and disordered breathing (13).
Observations from patients undergoing bariatric surgery suggest that weight-independent changes
in obese physiology contribute to improvements in disordered breathing such as OSA. Bariatric surgical procedures, such as the vertical sleeve gastrectomy (VSG) and the laparoscopic adjustable gastric
band (LAGB) lead to significant, sustained weight loss and improvements in glucose regulation (14).
However, VSG uniquely improves obesity-related physiology, including glucose metabolism and leptin
levels, through both weight-dependent and -independent mechanisms (15). This contrasts with the
LAGB, where metabolic improvements parallel total weight loss (14, 15). Interestingly, OSA resolution
1 year after VSG is approximately twice that of individuals undergoing LAGB (16, 17), suggesting that
improvements in obesity-related physiology may improve OSA above and beyond the effects of physical
body fat loss. Although few clinical studies have specifically examined the effects of bariatric surgery on
OHS, they report that bariatric surgery leads to acute and long-term improvements in arterial blood gases (18, 19); however, it is unclear if these improvements are due to physical body weight loss or overall
improvements in metabolic physiology. The role of leptin in chemosensitivity and disordered breathing
following bariatric surgery is largely unknown.
In the present study, we tested the hypothesis that VSG affects chemosensitivity and ventilatory drive
through a leptin-dependent mechanism using diet-induced obese wild-type (WT) mice, genetically obese,
leptin-deficient ob/ob mice, and our verified model of VSG (20). Using whole-body plethysmography, we
determined baseline ventilation and the hypercapnia ventilatory response (HCVR) as preclinical markers
of disordered breathing reflecting the alterations observed in OHS and OSA patients (2, 21–24). Within
diet-induced obese WT mice, we found that VSG leads to an improvement in chemosensitivity and reductions in leptin, independent of body and fat mass. Leptin-deficient ob/ob mice undergoing VSG fail to
exhibit an improvement in HCVR; however, this can be restored with leptin treatment. Importantly, while
ob/ob mice undergoing VSG demonstrate significant reductions in body mass, fat mass, and improvements
in glucose metabolism, leptin deficiency prevents VSG-induced improvements in chemosensitivity. We conclude that VSG improves chemosensitivity and ventilatory drive through a leptin-dependent mechanism.

Results
The effect of VSG on body mass, fat mass, and caloric intake in WT mice. Prior to surgical intervention, high-fat
diet (HFD), pair-fed, and VSG groups were maintained on an HFD to induce obesity and all groups were
assessed for ventilation and HCVR (Figure 1A). The HFD led to an approximately 16-g increase in body
mass and an approximately 15-g increase in fat mass (Figure 1, B–D). On the day of surgery (day 0), mice
underwent either VSG or sham surgery (Figure 1A). Additionally, on day 0 mice in the pair-fed group
began caloric restriction to match the caloric intake of mice receiving the VSG (Figure 1A). Following
surgery, mice received follow-up ventilatory measures and a glucose tolerance test (Figure 1A). Surgery
acutely decreased body mass and fat mass in all animals maintained on the HFD (Figure 1, B–D). Three
weeks after surgical intervention, pair-fed and VSG animals maintained a significant and similar reduction in body mass and fat mass (Figure 1, B–D) without altering lean mass (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.124469DS1). As
designed, cumulative caloric intake at 4 days and 3 weeks after surgical intervention was similar between
pair-fed and VSG mice (Figure 1E) to control for weight loss from the bariatric surgical procedure. VSG
led to significant and sustained decreases in body mass and fat mass in part through a reduction in caloric
intake. Importantly, pair-fed and VSG mice exhibited similar body mass and fat mass 4 days and 3 weeks
after surgery. Therefore, any differences observed between pair-fed and VSG groups would be indicative of
weight-independent effects of the VSG bariatric surgical procedure.
The effect of VSG on glucose regulation in WT mice. In response to an oral gavage of glucose performed
4 weeks after surgery, VSG and pair-fed mice exhibited an overall improvement in glucose tolerance in
comparison with HFD-fed mice (Figure 1F). Blood glucose levels of HFD mice were significantly higher
than all other groups 30 and 60 minutes following the glucose gavage (Figure 1F). Furthermore, HFD-fed
mice also had elevated glucose values compared with chow and pair-fed groups prior to and 10 and 120
minutes following the glucose gavage. As expected, VSG mice exhibited a distinct glucose tolerance curve,
including elevated glucose 15 minutes after gavage and a significant decrease at 30 minutes, which has been
observed in other studies (25) (Figure 1F). Chow and pair-fed mice had similar glucose tolerance areas
insight.jci.org   https://doi.org/10.1172/jci.insight.124469
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Figure 1. Body mass, fat mass, caloric intake, and glucose tolerance of WT mice following VSG. Generalized protocol and group description (A), body
mass (B and D), fat mass (C), cumulative caloric intake (E), glucose tolerance in response to a mixed-meal oral gavage (oGTT, F), and corresponding area
under the curve (AUC, F insert) for WT, chow-fed mice receiving sham surgery (Chow, n = 10, black lines/bars), high-fat diet–fed mice receiving sham surgery (HFD, n = 14–15, blue lines/bars), high-fat diet–fed mice receiving vertical sleeve gastrectomy surgery (VSG, n = 14, green lines/bars), and high-fat diet
pair-fed mice receiving calories equivalent to the VSG group (Pair-fed, n = 16, dotted green lines/bars). ****P < 0.0001 versus all other groups at the same
time point. *P < 0.05, Chow versus HFD, Chow versus VSG, HFD versus Pair-fed, Pair-fed versus VSG. †P < 0.05, HFD versus Chow and Pair-fed. #P < 0.05,
HFD versus VSG. §P < 0.05, Pair-fed versus VSG. Different letters indicate significant differences (P < 0.05) between groups. P values indicate Tukey’s post
hoc comparisons from repeated-measures ANOVA or 1-way ANOVA. Data expressed as mean ± SEM. Plethy, plethysmograph.

under the curve (AUCs), whereas VSG exhibited an intermediate AUC not significantly different from
HFD or pair-fed/chow sham groups (Figure 1F). Thus, in this study, VSG led to improved glucose dynamics without a significant improvement in AUC.
The effect of VSG on ventilation and the HCVR in WT mice. Chemosensitivity in response to elevated carbon
dioxide (i.e., hypercapnia) was assessed by ventilatory response (i.e., the HCVR) expressed as the slope of minute ventilation versus carbon dioxide concentration. Prior to surgical intervention (i.e., at baseline), ventilation
insight.jci.org   https://doi.org/10.1172/jci.insight.124469
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Figure 2. Hypercapnic ventilatory response and leptin levels of WT mice following VSG. Hypercapnic ventilatory response (HCVR) per gram body mass
(ml/min/%CO2/g) (A), and circulating leptin levels (ng/ml) (B) in WT, chow-fed mice receiving sham surgery (Chow, n = 10, black bars), high-fat diet–fed
mice receiving sham surgery (HFD, n = 15, blue bars), high-fat diet–fed mice receiving vertical sleeve gastrectomy surgery (VSG, n = 14, green bars), and
high-fat diet pair-fed mice receiving calories equivalent to the VSG group (Pair-fed, n = 16, dotted green bars). *P < 0.05, **P < 0.01, ***P < 0.001 versus
Chow. Different letters indicate significant differences (P < 0.05) between groups. P values indicate Tukey’s post hoc comparisons from 1-way ANOVA.
Data expressed as mean ± SEM.

in response to a hypercapnic challenge was higher in diet-induced obese mice (Supplemental Figure 2D). This
is consistent with clinical data that demonstrate that obesity increases HCVR to protect against the respiratory
depression associated with an increased body mass (26, 27). Diet-induced obesity also reduced baseline ventilation frequency in normal room air conditions, without effecting minute ventilation or tidal volume (Supplemental Figure 2, A–C). After surgical intervention, the animals exhibited significantly different body masses over
time in addition to different body masses between groups. Since HCVR is known to be affected by body mass
(28), we normalized each animal’s HCVR to its body mass at the time of testing (Figure 2A) to better determine
how HCVR responds to our specific experimental manipulations. Clinically, a similar procedure is done by
normalizing HCVR to an individual’s surface area or height (29), allowing one to draw conclusions about chemosensitivity relative to increasing body mass. When expressed as HCVR per gram body mass, chemosensitivity
compensation was similar between obese and lean mice prior to any surgical intervention (Figure 2A). However,
we observed a trend (P = 0.06) for decreased chemosensitivity relative to body mass within obese mice, suggesting that obesity itself may lead to impairments in chemosensitivity compensation in alignment with OHS.
This trend becomes significant 4 days after surgical intervention, when all animals maintained on the HFD (i.e.,
HFD, pair-fed, and VSG groups) exhibited a significant decrease in their ability to mount an HCVR appropriate for their body mass (Figure 2A). At this time, HFD, pair-fed, and VSG groups were of similar weight and
weighed significantly more than the chow control group (Figure 1B, P < 0.0001). Three weeks following surgical
intervention, only animals undergoing the VSG were able to mount a chemosensitivity response appropriate for
their body mass and similar to that of a lean control (Figure 2A). Importantly, at this time, HCVR was increased
in animals receiving the VSG compared with those in the pair-fed group, despite both groups having a similar
body mass, fat mass, and caloric intake (Figure 1, B–E). Taken together, these data demonstrate that chemosensitivity compensation per gram body mass is reduced with obesity (as observed within HFD and pair-fed groups)
but can be corrected with VSG independent of changes in body mass and/or fat mass. However, weight loss
alone is unable to improve HCVR or chemosensitivity compensation per gram body mass. This observation
suggests that weight-independent component(s) of the VSG may restore chemosensitivity and the HCVR.
The effect of VSG on leptin in WT mice. Owing to leptin’s involvement in ventilatory drive and HCVR
(11, 13, 30), we examined circulating plasma leptin levels directly following ventilatory testing 4 days
and 3 weeks after surgical intervention. As expected, leptin was lowest in lean, WT mice and highest
in HFD mice (Figure 2B). Pair-fed and VSG mice exhibited intermediate leptin levels, lower than HFD
but higher than chow. Interestingly, 4 days after surgical intervention, pair-fed and VSG leptin levels
were lower than HFD (Figure 2B, P < 0.05), although all groups were of similar weight. Three weeks
after surgical intervention, when pair-fed and VSG groups exhibited similar body mass and fat mass
(Figure 1C), leptin was significantly lower in mice undergoing VSG (Figure 2B, P < 0.05). Indeed,
mice undergoing VSG had significantly less leptin (ng/ml) per gram fat mass (1.31 ± 0.06 g) compared
with pair-fed mice (1.78 ± 0.06 g, P < 0.0001). These data point to the ability of the VSG surgery to
alter leptin levels independent of body weight or fat mass in a manner consistent with decreased leptin
resistance (7).
insight.jci.org   https://doi.org/10.1172/jci.insight.124469
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The effect of VSG on body mass, fat mass, and caloric intake in leptin-deficient ob/ob mice. To determine if
leptin was responsible for the WT’s improvements in HCVR following VSG, we repeated the experimental
design in leptin-deficient ob/ob mice (Figure 3A). All ob/ob mice were maintained on a standard chow diet
and received either sham or VSG surgery. Additionally, a leptin-treatment group received daily leptin (10
μg/day) and a pair-fed group was calorically restricted to match the caloric intake of leptin-treated mice.
Prior to surgical intervention, all groups were of similar weight (average 47.5 ± 0.6 g, Figure 3A) and had
similar fat and lean mass (Figure 3C and Supplemental Figure 3). As expected, sham control ob/ob mice
gained weight over the course of the study; however, all other groups lost weight over the course of the
study (Figure 3, B–D). Acutely, 5 days after surgical intervention, there were no significant differences in
body mass between the groups (Figure 3, B and D). However, at 3 weeks after surgical intervention, there
were significant differences in body mass and fat mass. Sham control mice weighed the most and had the
highest fat mass (Figure 3, B–D; P < 0.01). Leptin-treated mice weighed the least, with the corresponding
least amount of fat mass (Figure 3, B–D; P < 0.05). VSG and pair-fed groups exhibited equal body mass
and fat mass, intermediate between sham control and leptin groups (Figure 3, B–D). There was also a
small yet significant reduction in lean mass within the pair-fed group 3 weeks after surgical intervention
(Supplemental Figure 3), perhaps due to an exaggerated catabolic response to the caloric restriction (31) in
the absence of leptin signaling. Body mass and fat mass loss in leptin-treated and pair-fed mice is in part
supported by a reduction in cumulative caloric intake (Figure 3E, P < 0.05). Leptin-treated and pair-fed
animals, by design, consumed similar calories over the course of the experiment. Sham control exhibited
higher caloric intake by 5 days and 3 weeks after surgical intervention. While VSG showed a trend toward
a reduction in cumulative caloric intake, it was not significantly different from sham control. These data
demonstrate 2 key observations: (a) leptin reduces food intake and induces weight loss beyond caloric
reduction alone, most likely via increases in energy expenditure (32); and (b) VSG induces weight loss independent of leptin. Importantly, because leptin, pair-fed, and VSG groups demonstrate significant weight
loss, these data allow one to determine how glucose tolerance and chemosensitivity are specifically affected
by leptin or VSG independent of other confounding variables such as body mass.
The effect of VSG on glucose regulation in ob/ob mice. In response to an oral gavage of glucose, sham
control ob/ob mice exhibited impaired glucose tolerance in comparison with all other groups (Figure 3F,
P < 0.05). Strikingly, despite an approximately 10-g difference in body weight, VSG and leptin groups
exhibited similar glucose tolerance, yet both were profoundly improved compared with sham control
(Figure 3F, P < 0.05). Moreover, pair-fed ob/ob mice did not demonstrate an improvement in glucose
tolerance, despite losing weight and weighing roughly the same as the VSG group (Figure 3F). Taken
together, these data demonstrate that the VSG improves glucose tolerance in part through body mass–,
fat mass–, and leptin-independent mechanisms.
The effect of VSG on ventilation, the HCVR, and leptin in ob/ob mice. Prior to surgical intervention, all ob/ob
mice exhibited a similar HCVR (Supplemental Figure 4D), approximately half that of WT mice (Supplemental
Figure 2D). Baseline ventilation under room air conditions was not significantly different between ob/ob groups
(Supplemental Figure 4, A–C). Five days after surgical intervention, and before a divergence of body weights
between the groups, HCVR per gram body mass was exclusively increased within mice receiving leptin (Figure
4A, P < 0.05). Three weeks after surgical intervention, mice within the leptin group continued to be the only
ob/ob mice to experience an elevated chemosensitivity compensation per gram of body mass (Figure 4A, P <
0.0001). Plasma leptin levels were verified 3 weeks after surgical intervention, immediately after plethysmography. As expected, all ob/ob mice, except those treated with leptin, had leptin levels below the level of detection
(Figure 4B). It is notable that leptin-treated ob/ob mice and WT chow mice exhibited identical HCVRs (9.6 ± 0.3
vs. 9.6 ± 0.7 ml/min/%CO2; 2-tailed t test, P = 0.96) 3 weeks following surgical intervention (Supplemental Figure 2D and Supplemental Figure 4D), a time in which both groups exhibited similar body mass (29.31 ± 0.6 vs.
30.46 ± 1.1 g) and leptin levels (2.07 ± 0.2 vs. 3.233 ± 0.6 ng/ml) (2-tailed t tests, P = 0.38 and P = 0.09, respectively), although the leptin-treated ob/ob mice had more fat mass (2.16 ± 0.1 vs. 5.61 ± 0.9 g; 2-tailed t test, P <
0.01). Pair-fed ob/ob mice exhibited a blunted HCVR over the course of the experiment and, like their WT counterparts, failed to increase chemosensitivity compensation per gram body mass (Figure 4A, P > 0.05). Unlike
WT animals, ob/ob mice undergoing VSG did not experience an increase in chemosensitivity compensation per
gram body mass and, indeed, exhibited a blunted HCVR throughout the experiment (Figure 4A). This observation is particularly intriguing given that there were no chronic, significant differences in body mass (38.5 ± 1.2
vs. 40.1 ± 2.1 g; P = 0.52) or fat mass (12.5 ± 1.1 vs. 15.7 ± 1.6 g; P = 0.12) between WT VSG (Figure 1, B–D)
insight.jci.org   https://doi.org/10.1172/jci.insight.124469
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Figure 3. Body mass, fat mass, caloric intake, and glucose tolerance of leptin-deficient ob/ob mice following VSG. Generalized protocol and group
description (A), body mass (B and D), fat mass (C), cumulative caloric intake (E), glucose tolerance in response to a mixed-meal oral gavage (oGTT, F), and
corresponding area under the curve (AUC, F insert) for chow-fed ob/ob mice receiving sham surgery (Sham Control, n = 11, light blue lines/bars), daily leptin
treatment (Leptin, n = 10, orange lines/bars), pair-feeding yoked to leptin group (Pair-fed, n = 11, dotted orange lines/bars), or vertical sleeve gastrectomy
surgery (VSG, n = 6, light green lines/bars). *P < 0.05, **P < 0.01, ****P < 0.0001 versus all other groups at the same time point. †P < 0.05, ††P < 0.01
Leptin versus Sham Control and Pair-fed. ##P < 0.01 VSG versus Sham Control and Pair-fed. §§P < 0.01 Sham Control versus Leptin and VSG. Different letters indicate significant differences (P < 0.05) between groups. P values indicate Tukey’s post hoc comparisons from repeated-measures ANOVA or 1-way
ANOVA. Data expressed as mean ± SEM. Plethy, plethysmograph.

and ob/ob VSG (Figure 3, B–D) groups, underscoring the importance of leptin in the ventilatory response to
hypercapnia independent of body and fat mass. Finally, since VSG leads to leptin-independent improvements
in glucose metabolism without improving HCVR, it suggests that improvements in HCVR require leptin action
and are not dependent on other confounding improvements in glucose metabolism.
These data highlight a number of key findings: (a) leptin treatment rescues ventilation and chemosensitivity of ob/ob mice independent of body and fat mass; (b) as observed in WT mice, weight loss alone
is unable to improve HCVR or chemosensitivity compensation per gram body mass; (c) VSG is unable to
increase HCVR and chemosensitivity compensation without leptin signaling; and (d) improvements in
glucose metabolism alone are insufficient to improve HCVR.
insight.jci.org   https://doi.org/10.1172/jci.insight.124469
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Figure 4. Hypercapnic ventilatory response and leptin levels of leptin-deficient ob/ob mice following VSG. Hypercapnic ventilatory response (HCVR) per
gram body mass (ml/min/%CO2/g) (A), and circulating leptin levels (ng/ml) (B) in chow-fed ob/ob mice receiving sham surgery (Sham Control, n = 11, light
blue bars), daily leptin treatment (Leptin, n = 10, orange bars), pair-feeding yoked to leptin group (Pair-fed, n = 11, dotted orange bars), or vertical sleeve
gastrectomy surgery (VSG, n = 6, light green bars). ****P < 0.0001 versus all other groups at the same time point. Different letters indicate significant
differences (P < 0.05) between groups. P values indicate Tukey’s post hoc comparisons from 1-way ANOVA. Data expressed as mean ± SEM.

Discussion
In the current study, we segregate the mechanical load of obesity from the metabolic disturbances imposed
by obesity by utilizing diet-induced obese mice undergoing VSG or weight-matched caloric restriction. As a
metabolic surgery, the VSG procedure is known to modulate obese physiology (including glycemic control
and leptin levels) independent from weight loss. Thus, this model offers a unique opportunity to explore
the physical versus the physiological aspects of obesity and the specific effects on disordered breathing and
chemosensitivity. In WT mice, we found that VSG leads to improvements in disordered breathing and chemosensitivity appropriate for the animals’ body mass that are not observed in weight-matched controls. To
our knowledge, this is the first study to report on ventilation and/or chemosensitivity following metabolic
surgery in a preclinical mouse model. Yet, our data are in agreement with clinical observations that individuals undergoing bariatric or metabolic surgery exhibit a profound improvement in disordered breathing
shortly after surgery (33) and improvements in OHS symptoms (18, 19). We further show that VSG is
unable to improve ventilation or chemosensitivity in leptin-deficient ob/ob mice. In agreement with previous reports (11, 30), exogenous leptin treatment in ob/ob mice restores a WT ventilation response before
significant body/fat mass is lost. Together, these results indicate that VSG can improve ventilatory control
and chemosensitivity independent of body mass and through a leptin-dependent mechanism.
Strikingly, we did not observe an improvement in ventilatory drive from weight-loss alone. While the traditional clinical assumption has been that nonsurgical weight loss would lead to improvements in OHS on par
with surgically induced weight loss (5), to our knowledge these data have not been specifically reported. Instead,
most of the observations regarding the effect of weight loss on OHS has been from morbidly obese, bariatric
surgery patients. Although it remains to be tested within the clinical population, the present study would suggest
that nonsurgical weight loss (e.g., caloric restriction) would not have the same effect on OHS symptoms as metabolic surgery, even if the same amount of weight loss could be achieved by each method. Thus, these data shed
light on the contribution of mechanical load in the pathogenesis of OHS, downgrading the relative importance
of physical weight and underscoring the physiological contribution in the pathogenesis of OHS.
While the mechanism by which metabolic surgery leads to weight-independent changes in physiology
remain an active research question, a predominant view is that metabolic surgery exerts its actions via the
brain. This hypothesis is validated by a number of studies showing that metabolic surgery can alter complex behaviors, such as addiction (34) and food choice (35), as well as dramatic changes in neurohormonal
gut peptides (36) including an almost 10-fold increase in glucagon-like peptide 1 (GLP-1) (37). However,
not all physiological changes following VSG are critical for weight loss or glucose regulation. For example,
despite the known involvement of GLP-1 in glucose regulation, mouse models lacking GLP-1 receptors
specifically within β cells (37) or throughout the whole body (38) successfully lose weight and exhibit an
improvement in glucose tolerance following VSG. Similarly, while leptin is not necessary for the weight
loss or metabolic outcomes following VSG (39, 40), leptin is altered following metabolic surgery (41). In
agreement with these observations, we report VSG-induced improvements in glucose tolerance in ob/ob
mice and reductions in WT leptin levels, both effected independent of weight loss.
insight.jci.org   https://doi.org/10.1172/jci.insight.124469
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Notably, while metabolic surgery does not result in an increased metabolic response to leptin administration (e.g., a decrease in food intake) (41), it remains possible that leptin’s action on nonmetabolic parameters such as disordered breathing and chemosensitivity is improved following VSG. We have recently
demonstrated that modulating leptin signaling at the neuronal level, specifically within the periaqueductal
gray, leads to a disordered-breathing phenotype and a reduction in HCVR (42). This opens the possibility
that VSG not only affects the brain’s control of feeding behaviors and glucose regulation, but ventilation
and chemosensitivity as well. As mounting evidence suggests that metabolic surgeries can improve glucose regulation through weight-independent pathways, it is hardly surprising that other pathophysiological
states associated with obesity may also be improved.
It is possible that our interpretation of these data is skewed by the disproportional loss of ob/ob mice
as compared to WT mice following VSG. The excluded animals may have exhibited differential responses
and the surviving mice thus biased the results. While we cannot be certain of the former, we can report that
the excluded ob/ob mice did not demonstrate any initial weight, food intake, or other observable differences
from those that completed the study. In regard to the latter, the number of ob/ob mice that completed the
study was sufficient to draw statistical comparisons and our metabolic conclusions are in agreement with
others’ reports (39, 40).
These data provide evidence that the pathogenesis of OHS is rooted in physiological mechanisms that,
like metabolic surgery (14), go beyond physically restrictive mechanisms and implicate alterations in the
gut-brain axis. The ability of a peripheral surgery to affect complex physiology and behavior has profound
implications for future therapeutic targets to treat obesity, OHS, and other disordered breathing such as
OSA. Indeed, these results open the possibility for metabolic surgeries and potentially leptin to be used as
novel treatments for chemosensitivity and disordered breathing.

Methods
Study design. To determine the effect of body weight and VSG on disordered breathing and leptin levels,
we utilized C57BL6/J WT male mice divided into 4 groups: (a) A chow sham group was maintained on
a standard chow diet and received a sham surgery to mirror nonspecific effects of the VSG surgery. (b) An
HFD sham group was maintained on a 45% kcal HFD before and after receiving a sham surgery. (c) An
HFD VSG group was maintained on a 45% kcal diet before and after receiving the VSG surgery. (d) An
HFD pair-fed group was pair-fed with the VSG group, meaning that mice in HFD pair-fed group received
the same amount of kcal per day as mice in the HFD VSG group elected to eat. In this way, the HFD pairfed group was on a restricted calorie diet matching the calories experienced by the VSG mice and could
control for VSG-independent weight loss.
To determine if VSG can lead to leptin-independent effects on disordered breathing, leptin-deficient
ob/ob mice were divided into 4 groups. Owing to the ob/ob mouse’s genetic propensity toward obesity, an
HFD is not necessary to induce obesity; all ob/ob mice were maintained on a standard chow diet. Group
1: A sham group was implanted with a mini-osmotic pump delivering vehicle (water) and received a
sham surgery to mirror nonspecific effects of the VSG surgery. Group 2: A VSG group was implanted
with a mini-osmotic pump delivering vehicle (water) and received the VSG surgery. Group 3: A leptin
group was implanted with a mini-osmotic pump delivering leptin and received a sham surgery. Group 4:
A pair-fed group was pair-fed with the leptin group, meaning that mice in the pair-fed group received the
same amount of kcal per day as mice in the leptin group elected to eat. In this way, the pair-fed group
was on a restricted calorie diet matching the weight loss and allowed one to make conclusions about
weight loss independent of VSG.
For the outlined experiments, sample size was determined based on previous validated mouse studies
using the VSG model (43). For all non-VSG groups, the final analyzed n ranged from 10–16 per group. For
VSG groups, the final analyzed n was 14 C57BL6/J mice and 6 ob/ob mice. Among all the C57BL6/J mice,
7 out of 62 (11%) were excluded from analysis due to failure to recover from the VSG surgery (n = 3) or
from intestinal obstruction and/or infection (n = 4). Among all ob/ob mice, 12 out of 50 (24%) were excluded from analysis due to failure to recover from the VSG surgery (n = 8), from intestinal obstruction and/or
infection (n = 3), or death from an unknown cause (n = 1). The relatively high number of ob/ob mice failing
to recover from the VSG is believed to be independent of the VSG procedure itself. Instead, we believe the
recovery rate in ob/ob mice is affected by the mouse’s genetic propensity to hypothermia. Ob/ob mice have
been observed to have lower body temperatures and energy expenditure (44).
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For all collected measurements, except body weight and daily food intake measures, the experimenter
was blinded to the experimental group. For measurement of body weight and food intake, it is necessary to
know the group information as an additional health check for recovery after the surgery.
Animals. Mice were housed in a standard vivarium room under a standard 12-hour light/12-hour dark
cycle. C57BL6/J (WT) and ob/ob mice were ordered from the Jackson Laboratory at 6–8 weeks of age. All
mice were singly housed. To induce obesity in diet-induced obese WT mice, mice were fed an HFD (45%
fat, 4.54 kcal/g, D12451 Research Diets) for 10 weeks before surgery and were maintained on the same diet
after surgery. All mice had ad libitum access to food, with the exception of the pair-fed groups that were
maintained on a calorically restricted diet. For pair-fed mice, the restricted food amount was calculated
daily based on the average intake of the paired group (i.e., WT VSG or ob/ob Leptin) and administered
once per day. For all studies, groups were age matched and divided to ensure equal body weights among
similarly genotyped animals prior to surgical intervention.
Baseline ventilation and HCVR. To measure baseline respiration and the response to hypercapnia in freely
moving, conscious mice we used a whole-body plethysmograph (Emka Technologies). A mouse was placed
inside the plethysmograph chamber and habituated to its new environment for 30 minutes prior to measurement collection (only one mouse was placed inside a single chamber at a given time). During the habituation
period, air exchange allows the animal to breath room air. Next, animals were exposed to a mixture of 21%
oxygen and 79% nitrogen (to mirror room air conditions) and baseline respiration, including breathing rate,
inspiration/expiration time, volume and flow (relative changes from baseline), relaxation time, end-inspiration and end-expiration pause, and enhanced pause were recorded. Then, the chamber gases were changed
to deliver hypercapnic environments over 4-minute increments (similar to the protocol used in ref. 11) at 3%,
5%, and 8% carbon dioxide separated by 5-minute recovery periods of a room air mix. For all hypercapnic
exposures, oxygen was maintained at 21% and nitrogen concentration was modified to allow for changes in
carbon dioxide. Similar respiratory measures were recorded as during baseline ventilation. Animals were
monitored continuously and kept awake by gentle tapping on the chamber to prevent sleep-associated changes in HCVR (11). HCVR was calculated by the slope of CO2% versus minute ventilation.
Glucose tolerance test. For the oral glucose tolerance test, all animals were fasted for 6 hours prior to an
oral gavage of 200 μl Ensure Plus (Abbott Laboratories). All glucose was measured by glucometer prior to
gavage/injection (time 0), and then 15, 30, 60, and 120 minutes after gavage/injection. Blood was collected
from the tip of the tail by cutting a small amount of the tail and gently massaging the blood out. Animals
were excluded from analysis based on pre-established criteria, i.e., if blood glucose did not rise significantly
over the 2-hour period or if the presence of diarrhea was observed, indicating a failed glucose gavage. One
mouse was excluded from the test due to the presence of diarrhea (a WT HFD mouse).
VSG. All mice were exposed to liquid Osmolite (Abbott Laboratories) before surgery. Surgery began
when mice were 11–16 weeks old and followed surgical procedures as previously indicated (45). Briefly,
after isoflurane anesthesia, all animals (including those in the sham surgery condition) received a midline
abdominal skin incision, followed by an incision in the underlying muscle wall. VSG mice had approximately 80% of the stomach resected along the major curvature, while sham mice had their stomach
exposed and manipulated but not cut. Following surgery, mice were maintained on liquid Osmolite for 4
days, solid food was returned on the fourth day along with Osmolite, and on the fifth day mice were only
provided solid food from then on. Metacam was provided daily for 4 days after surgery for pain.
Leptin treatment. Leptin was delivered by mini-osmotic pump (Allzet) for 6 weeks at a rate of 10
μg/day. This dose of leptin was selected in an effort to achieve circulating leptin levels similar to WT
chow-fed control mice. Pumps were implanted subcutaneously in the scapular region of the mouse
during the time of VSG or sham surgery. Vehicle pumps, delivering water, were implanted into all
ob/ob mice not receiving leptin treatment. In accordance with the manufacturer’s guidelines, pumps
reached steady-state release in approximately 48 hours. Therefore, 5 days after surgery is equivalent to
day 3 of steady-rate leptin treatment.
Body mass, fat mass, and food intake measurements. Body weight and food intake measurements were measured over the course of the experiment daily or 2 times per week. Food was measured by manually removing food from the cage to determine weight. Total fat and lean mass were calculated using a whole-body
composition analyzer (EchoMRI).
Leptin measurements. Blood was drawn for leptin measurements immediately after exposure to the
hypercapnia challenge in the whole-body plethysmograph. Plasma was collected and tested via a Mouse
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Leptin Kit (Meso Scale Diagnostics). Blood was collected after hypocapnia exposure to limit stress prior to
ventilation measurements.
Statistics. Statistical analysis was performed using GraphPad Prism version 5.0. Statistical significance
was determined either by repeated measures or 1-way ANOVA followed by Tukey’s post hoc test. Results
were considered statistically significant when P < 0.05 (2-tailed design).
Study approval. All studies were reviewed, approved by, and performed according to the guidelines of
the Institutional Animal Care and Use Committee of the University of Michigan.
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